Search Results for "apomorphine"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for apomorphine. Results 1 to 4 of 4 total matches.
See also: Apokyn
Sublingual Apomorphine (Kynmobi) for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020 (Issue 1609)
Sublingual Apomorphine (Kynmobi) for Parkinson's Disease ...
The FDA has approved a sublingual fi lm formulation
of the nonergot dopamine agonist apomorphine
(Kynmobi – Sunovion) for acute, intermittent treatment
of "off" episodes in patients with Parkinson's disease
(PD). A subcutaneous formulation of apomorphine
(Apokyn) has been available for years for the same
indication in patients with advanced PD.
Drugs for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021 (Issue 1618)
levodopa, or subcutaneous or
sublingual apomorphine can be used for rescue treatment of
off episodes ...
The motor symptoms of Parkinson's disease (PD) are
caused primarily by degeneration of dopaminergic
neurons in the substantia nigra. The nonmotor symptoms
of the disease are thought to be caused by degeneration of
other neurotransmitter systems. No disease-modifying
drugs are available for treatment of PD.
Comparison Table: Drugs for Parkinson's Disease (online only)
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021 (Issue 1618)
dyschromia have
occurred with the rotigotine patch
iInjection-site reactions can occur with SC apomorphine ...
View the Comparison Table: Drugs for Parkinson's Disease
Opicapone (Ongentys) - A COMT Inhibitor for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Jan 11, 2021 (Issue 1615)
) for Parkinson’s disease. Med Lett
Drugs Ther 2020; 62:20.
4. Sublingual apomorphine (Kynmobi) for Parkinson’s ...
The FDA has approved opicapone (Ongentys –
Neurocrine), a peripherally-acting reversible catechol-O-methyltransferase (COMT) inhibitor, for oral use as an
adjunct to carbidopa/levodopa in adults with Parkinson’s
disease (PD) who experience "off" episodes. It is the
third COMT inhibitor to be approved for this indication;
tolcapone (Tasmar, and generics) and entacapone
(Comtan, and generics) were approved earlier. Opicapone
has been available in Europe since 2016.